Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn Screening
Recruiting now · Not applicable
Conditions studied: Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD)
In brief
The Active NBS Liege study is a monocentric, academic, fully remote, observational study designed to validate digital measures of motor development in children with spinal muscular atrophy (SMA) or Duchenne muscular dystrophy (DMD) identified through newborn screening, family testing, or incidental diagnosis. The study will enroll 100 children and follow them longitudinally for up to 30 months. Participants are remotely recruited, and all procedures, including consent, questionnaires, and follow-up visits, are conducted by phone or video conferencing without any hospital visits. Children will use age-appropriate wearable devices at home: MAIJU®, a sensorized garment for non-ambulant infants, and Syde®, an ankle-worn sensor for ambulant children. Data collection includes digital motor endpoints, clinical information, and quality of life (PedsQL). Primary objectives are to validate digital biomarkers of motor development, while secondary objectives include early identification of motor deficits, modeling motor trajectories, and quantifying genotype-related differences. Exploratory analyses will assess gait parameters such as stride velocity 95th centile (SV95C) and compare motor outcomes across genetic profiles and treatment exposure. Risks are minimal, limited to the use of non-invasive sensors with no known side effects.
Key facts
- Study ID
- NCT07286565
- Run by
- Centre Hospitalier Universitaire de Liege
- People needed
- 100
- Starts
- 2025-12-01
- Expected to finish
- 2028-08-01
- Last updated by the study team
- 2025-12-16
Who can join
Age: 0 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Genetically confirmed SMA and avalaible MSNA2 copy number:
- Identified by newborn screening,
- Identified by family screening, or incidental diagnosis in pre-symptomatic stage
- Treated (or follow-up possible for patients with 4 SMN2 copies)
- Genetically confirmed DMD:
- Identified by newborn screening,
- Identified by family screening, or incidental diagnosis in pre-symptomatic stage
- Age < 4 years at inclusion
- Legal guardian able to provide informed consent
You may not qualify if…
- Any acute or chronic condition that, in the investigator's opinion, significantly interferes with assessments and/or motor development.
- Participation in a therapeutic trial.
- Lack of internet connection.
Where it is running
- Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle — Liège, Belgium (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.